WO1994013697A1 - Treatment of septic shock with conjugated biologically active peptides - Google Patents
Treatment of septic shock with conjugated biologically active peptides Download PDFInfo
- Publication number
- WO1994013697A1 WO1994013697A1 PCT/US1993/011841 US9311841W WO9413697A1 WO 1994013697 A1 WO1994013697 A1 WO 1994013697A1 US 9311841 W US9311841 W US 9311841W WO 9413697 A1 WO9413697 A1 WO 9413697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- peptide
- lys
- hydrophilic
- basic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to the treatment of septic shock. More particularly, this invention relates to the treatment of septic shock by administering biologically active peptides including conjugate moieties.
- Septic shock is a type of shock associated with
- the infection is produced by Gram-negative bacteria (such as, for example, E. coli, Pseudomonas species, and Bacteroides species), although other bacteria, viruses, fungi, and protozoa may also be causes.
- Gram-negative bacteria such as, for example, E. coli, Pseudomonas species, and Bacteroides species
- the shock is believed to be caused by the action of endotoxins (such as the liposaccharide or LPS in bacterial cell walls), other products of the infectious agent, or host mediators released in response to the
- Bacterial endotoxin such as LPS
- LPS Bacterial endotoxin
- the majority of damage induced from the presence of LPS is not due to the LPS itself, but is a result of the body,s complex reaction to the foreign LPS. This response is mediated by immune cell activation and the resultant damage that these activated cells cause to the host tissues.
- Treatment following the initial signs of septic shock includes the infusion of normal saline or lactated Ringer,s solution. If the shock persists, then an aggressive fluid challenge may be started, and the use of dopamine and/or norepinephrine may be recommended. More recent approaches to the treatment of septic shock are directed to the killing of bacteria and neutralizing LPS endotoxin with specific monoclonal antibodies; human bacteria permeability
- BPI body weight increasing protein
- EDP endotoxin neutralizing protein
- European Patent Application No. 428,486 discloses a conjugate of polymyxin B and a carrier, which may be
- the carrier may be a polysaccharide such as dextran or hydroxyethyl starch; a protein such as albumin; polyvinylpyrrolidone;
- polyethylene glycol or polyvinyl alcohol.
- a compound which is a conjugate of: (i) a biologically active amphiphilic peptide, said peptide being an ion channel-forming peptide; and (ii) a conjugate moiety selected from the group consisting of: (a) carbohydrates; (b) proteins; (c) polyvinylpyrrolidone; (d) polyalkylene glycols; and (e) polyvinyl alcohol.
- the compounds of the present invention are particularly applicable to the treatment of septic shock in that such compounds neutralize bacterial endotoxins.
- the peptides are positively charged, while in general, the bacterial endotoxins are negatively charged.
- the compounds are particularly useful in that such compounds neutralize bacterial endotoxins without neutralizing essential proteins in plasma (such as heparin, for example).
- the compounds can be constructed such that they have a longer duration of activity than unconjugated peptides.
- the conjugate moiety may be attached to the peptide at the C-terminal, at the N-terminal, or to an internal amino acid residue. It is to be noted, however, that the
- conjugate moiety should be attached to the peptide such that the peptide retains its positive charge.
- the conjugate moiety is a
- Carbohydrates which may be conjugated to the peptide include, but are not limited to, dextran,
- the carbohydrate is dextran. In another embodiment, the carbohydrate is hetastarch.
- Such carbohydrates may be conjugated to the peptide at the C-terminal, the N-terminal, or to an internal amino acid.
- the carbohydrate may be attached through a carbamate linkage, through an amine linkage, through an ester linkage, or through bifunctional crosslinking agents.
- Ester linkages of the peptide with the carbohydrate may be formed by reacting the peptide and the carbohydrate in the presence of EDCI and DMAP.
- the C-terminus of the peptide reacts with an -OH group of the carbohydrate to form an ester bond.
- Amine linkages may be formed by oxidizing the
- aldehyde carbohydrate with periodate to form aldehyde groups.
- the aldehyde is then reacted with an amino group on the peptide to form a Schiff base which then can be reduced to an amine.
- the product is an amino-carbohydrate.
- amino-carbohydrate can be reacted with a peptide to form an amide linkage.
- Carbamate linkages may be formed by treating the carbohydrate with 1-cyano-4-dimethyl-amino pyridinium tetrafluoroborate (CDAP), and then reacting the treated carbohydrate with a peptide having a free amino group to form a carbamate linkage.
- CDAP 1-cyano-4-dimethyl-amino pyridinium tetrafluoroborate
- Bifunctional crosslinking agents which may be employed for attacking the carbohydrate to the peptide include, but are not limited to, malimido groups, - S - S - O groups, and groups. Such groups may be attached to the carbohydrate first by attaching a -COOH group to the functional group, and then reacting the modified functional group with an -OH group of the carbohydrate to provide a carbohydrate containing the functional group.
- the peptide may be coupled to the protein via disulfide, amide, ester, ether, or other forms of covalent bonds.
- Polyvinyl pyrrolidone may be attached to the peptide through ester linkages, through carbamate linkages, or through bifunctional crosslinking agents, such as those hereinabove described.
- Polyalkylene glycols which may be conjugated to the peptide include, but are not limited to, polyethylene glycol.
- the polyalkylene glycol may be attached to the peptide through ester linkages, carbamate linkages, or through bifunctional crosslinking agents, whereby free -OH groups of the polyalkylene glycol are reacted to form such
- the polyvinyl alcohol also may be attached to the peptide through the linkages hereinabove described.
- the biologically active amphiphilic peptides employed in the present invention are generally water-soluble to a concentration of at least 20 mg/ml at neutral pH in water.
- the structure of such peptide provides for flexibility of the peptide molecule.
- Such peptides are capable of forming an alpha-helix. When the peptide is placed in water, it does not assume an amphiphilic
- such peptides have at least 7 amino acids. In most cases, such peptides do not have in excess of 50 amino acids.
- the biologically active peptides are ion channel-forming peptides.
- An ion channel-forming peptide or ionophore is a peptide which increases the permeability for ions across a natural or synthetic lipid membrane.
- an ion channel-forming peptide is a peptide which has ion channel-forming
- amphiphilic peptide is a peptide which includes both hydrophobic and hydrophilic peptide regions.
- the compounds may be administered in an amount
- the compounds are administered in an amount of from about 1 ⁇ g/kg to about 5 mg/kg per host weight.
- the compounds may be administered to a host in vivo, such as, for example, through systemic administration, such as intravenous or intraperitoneal administration.
- the compounds are administered in combination with an acceptable pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
- an acceptable pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
- the compounds may also be used in combination with
- the peptide is a basic (positively charged) polypeptide having at least sixteen amino acids wherein the polypeptide includes at least eight hydrophobic amino acids and at least eight hydrophilic amino acids.
- hydrophobic amino acids are in groups of two adjacent amino acids, and each group of two hydrophobic amino acids is spaced from another group of two hydrophobic amino acids by at least one amino acid other than a hydrophobic amino acid (preferably at least two amino acids) and generally by no greater than four amino acids, and the amino acids between pairs of hydrophobic amino acids may or may not be hydrophilic.
- the hydrophilic amino acids are generally also in groups of two adjacent amino acids in which at least one of the two amino acids is a basic hydrophilic amino acid, with such groups of two hydrophilic amino acids being spaced from each other by at least one amino acid other than a
- hydrophilic amino acid preferably at least two amino acids and generally no greater than four amino acids, and the amino acids between pairs of hydrophilic amino acids may or may not be hydrophobic.
- the polypeptide comprises a chain of at least four groups of amino acids, with each group consisting of four amino acids. Two of the four amino acids in each group are hydrophobic amino acids, and two of the four amino acids in each group are hydrophilic, with at least one of the hydrophilic amino acids in each group being a basic hydrophilic amino acid and the other being a basic or neutral hydrophilic amino acid.
- the hydrophobic amino acids may be selected from the class consisting of Ala, Cys, Phe, Gly, lIe, Leu, Met, Pro, Val, Trp, Tyr, norleucine (Nle), norvaline (Nva), and cyclohexylalanine (Cha).
- the neutral hydrophilic amino acids may be selected from the class consisting of Asn, Gln, Ser, Thr and homoserine (Hse).
- the basic hydrophilic amino acids may be selected from the class consisting of Lys, Arg, His, Orn, homoarginine (Har), 2, 4-diaminobutyric acid
- Each of the groups of four amino acids may be of the sequence ABCD, BCDA, CDAB, or DABC, wherein A and B are each hydrophobic amino acids and may be the same or different, one of C or D is a basic hydrophilic amino acid, and the other of C or D is a basic or neutral hydrophilic amino acid and may be the same or different.
- the polypeptide chain may comprise 5 or 6 groups of this
- each of A, B, C and D may be the same in some or all of the groups or may be different in some or all of the groups.
- the polypeptide chain preferably has at least 20 amino acids, and no greater than 50 amino acids. It is to be understood, however, that the polypeptide does not have to consist entirely of the groups described above.
- polypeptide may have amino acids extending from either or both ends of the noted groups forming the polypeptide chain and/or there may be amino acids between one or more of the at least four groups and still remain within the scope of the invention.
- the groups of amino acids may be repeating groups of amino acids, or the amino acids in the various groups may vary provided that in each group of the at least four groups of amino acids there are two hydrophobic and two hydrophilic amino acids as hereinabove noted.
- the biologically active polypeptide may comprise a chain including at least four groups of amino acids, each containing four amino acids. Two of the four amino acids in each group are hydrophobic, at least one amino acid is basic hydrophilic, and the remaining one is basic or neutral hydrophilic, with the polypeptide chain preferably having at least 20 amino acids but no greater than 50 amino acids.
- each of the at least four groups of amino acids which are in the peptide chain is of the
- B are hydrophobic amino acids, one of C or D is a basic hydrophilic amino acid, and the other of C or D is basic or neutral hydrophilic amino acid.
- the resulting polypeptide chain therefore, may have one of the following sequences:
- X 1 is D; C-D- or B-C-D-, Y 1 is -A or -A-B or -A-B-C
- X 2 is A-, D-A- or C-D-A-
- Y 2 is -B, -B-C or B-C-D
- X 3 is B-, A-B-, D-A-B-
- Y 3 is -C, -C-D, -C-D-A
- X 4 is C-, B-C-, A-B-C-
- Y 4 is -D, -D-A, -D-A-B
- n is at least 4.
- the peptide chain may include amino acids between the hereinabove noted groups of four amino acids provided that the spacing between such groups and the charge on the amino acids does not change the characteristics of the peptide chain which provide amphiphilicity and a positive charge and do not adversely affect the folding characteristics of the chain to that which is significantly different from one in which the hereinabove noted group of four amino acids are not spaced from each other.
- the peptide may have amino acids extending from either end of the chain.
- the chains may have a
- Other amino acid sequences may also be attached to the "Ala” and/or the "Lys" end.
- the chain may have, for example, a C-D sequence before the first A-B-C-D group.
- other amino acid sequences may be attached to the "A" and/or the "D" end of one of these polypeptide chains.
- the peptide may be a magainin peptide.
- a magainin peptide is either a magainin such as magainin I, II or III or an analogue or derivative thereof.
- the magainin peptides preferably include the following basic peptide structure X 12 :
- a magainin peptide may include the following structure:
- R 11 , R 12 , R 14 and R 14a are as Previously
- a magainin peptide may also have the following
- R 16 where R 16 is a basic hydrophilic amino acid or asparagine or glutamine.
- R 17 is a neutral hydrophilic amino acid.
- a magainin peptide may also have the following
- X 12 , Y 12 and Z 12 are as previously defined and a is 0 or 1 and b is 0 or 1.
- the magainin peptides may also include the following basic peptide structure X 13 :
- R 14a are amino acids as hereinabove described.
- the magainin peptide may also include the following structure X 13 -Z 13 ; wherein X 13 is the hereinabove described basic peptide structure and Z 13 is
- R(16) n -(R17) n wherein R 11 , R 14 , R 14 a, R 15 , R 16 , and R 17 are as hereinabove described, and n is 0 or 1, and each n may be the same or different.
- the magainin peptides generally include at least fourteen amino acids and may include up to forty amino acids.
- a magainin peptide preferably has 22 or 23 amino acids. Accordingly, the hereinabove described basic peptide structures of a magainin peptide may include additional amino acids at the amino end or at the carboxyl end, or at both ends.
- magainin peptides having the following primary sequences as given in the accompanying sequence listing as well as appropriate analogues and derivatives thereof:
- Magainin peptides are described in Proc. Natl. Acad Sci. Vol. 84 pp. 5449-53 (Aug. 87).
- magainin peptides refers to the basic magainin structure as well as derivatives and analogs thereof, including but not limited to the representative derivatives or analogs.
- the peptide may be a PGLa peptide or an XPF peptide.
- a PGLa peptide is either PGLa or an analogue or
- the PGLa peptides preferably include the following basic peptide structure X 14 :
- the PGLa peptides generally include at least seventeen amino acids and may include as many as forty amino acids. Accordingly, the hereinabove described basic peptide
- structure for a PGLa peptide may include additional amino acids at the amino end or at the carboxyl end or at both the amino and carboxyl end.
- a PGLa peptide may have the
- R 11 and R 1 4 are as previously defined.
- a PGLa peptide may also have the following structure:
- R 11 is as previously defined.
- a PGLa peptide may also have the following structure:
- X 14 ; Y 14 and Z 14 are as previously defined, a is 0 or 1 and b is 0 or 1.
- An XPF peptide is either XPF or an analogue or
- the XPF peptides preferably include the following basic peptide structure X 16 :
- R 11 , R 1 2 , R 14 , R 15 and R 17 are as previously defined and R 18 is glutamine or asparagine or a basic hydrophilic, or hydrophobic amino acid and, n is 0 or 1.
- the XPF peptides generally include at least nineteen amino acids and may include up to forty amino acids.
- structure of XPF may include additional amino acids at the amino end, or at the carboxyl end or at both the amino and carboxyl ends.
- an XPF peptide may include the following structure:
- R 11 and R 14 are as previously defined.
- An XPF peptide may include the following structure:
- An XPF peptide may also have the following structure:
- the peptide may be a CPF peptide or appropriate analogue or derivative thereof.
- CPF peptides as well as analogues and derivatives thereof are herein sometimes referred to collectively as CPF peptides.
- the CPF peptide may be one which includes the following basic peptide structure X 20 : -R 21 -R 21 -R 22 -R 22 -R 21 -R 21 -R 23 -R 21 - -R 21 -R 21 -R 23 -R 21 -R 21 -R 24 -R 25 -R 21 - wherein R 21 is a hydrophobic amino acid;
- R 22 is a hydrophobic amino acid or a basic hydrophilic amino acid
- R 23 is a basic hydrophilic amino acid
- R 24 is a hydrophobic or neutral hydrophilic amino acid
- R 25 is a basic or neutral hydrophilic amino acid.
- hydrophobic amino acids are Ala, Cys, Phe, Gly, lIe, Leu, Met, Val, Trp, Tyr, norleucine (Nle), norvaline (Nva), and cyclohexylalanine (Cha).
- the neutral hydrophilic amino acids are Asn, Gln, Ser, Thr, and homoserine (Hse).
- the basic hydrophilic amino acids are Lys, Arg, His, Orn, homoarginine (Har), 2, 4-diaminobutyric acid (Dbu), and p-aminophenylalanine.
- the CPF peptide may include only the hereinabove noted amino acids or may include additional amino acids at the amino and/or carboxyl end or both the amino and carboxyl end. In general, the peptide does not include more than 40 amino acids.
- the CPF peptides including the above basic structure preferably have from 1 to 4 additional amino acids at the amino end.
- the carboxyl end of the basic peptide structure may also have additional amino acids which may range from 1 to 13 additional amino acids.
- the basic structure may have from 1 to 7 additional amino acids at the carboxyl end, which may be represented as follows:
- X is the hereinabove defined basic peptide structure and Z 20 is
- Preferred peptides may be represented by the following structural formula
- Y( 20 ) a - X 20 - (Z 20 ) b wherein X 20 , Y 20 and Z 20 are as previously defined and a is 0 or 1 and b is 0 or 1.
- the peptide may include one of the following basic structures X 31 through X 37 wherein:
- X 31 is -[R 31 -R 32 -R 32 -R 33 -R 31 -R 32 -R 32 ]- n ;
- X 32 is -[R 32 -R 32 -R 33 -R 31 -R 32 -R 32 -R 31 ]- n ;
- X 33 is -[R 32 -R 33 -R 31 -R 32 -R 32 -R 31 -R 32 ]- n ;
- X 34 is -[R 33 -R 31 -R 32 -R 32 -R 31 -R 32 -R 32 ]- n ;
- X 35 is -[R 31 -R 32 -R 32 -R 31 -R 32 -R 32 -R 33 ]- n ;
- X 36 is -[R 32 -R 32 -R 31 -R 32 -R 32 -R 33 -R 31 ]- n ;
- X 37 is -[R 32 -R 31 -R 32 -R 32 -R 33 -R 31 -R 32 ]- n ;
- R 31 is a basic hydrophilic amino acid
- R 32 is a hydrophobic amino acid
- R 33 is a neutral hydrophilic, basic hydrophilic, or hydrophobic amino acid
- n is from 2 to 5.
- the basic hydrophilic amino acids may be selected from the class consisting of Lys, Arg, His, Orn, homoarginine (Har), 2,4-diaminobutyric acid (Dbu), and
- the hydrophobic amino acids may be selected from the class consisting of Ala, Cys, Phe, Gly, Ile, Leu, Met, Pro, Val, Trp and Tyr, norleucine (Nle), norvaline (Nva), and cyclohexylalanine (Cha).
- the neutral hydrophilic amino acids may be selected from the class consisting of Asn, Gln, Ser, Thr, and homoserine (Hse).
- the peptide when the peptide includes the structure X 31 .
- the peptide may include the following structure:
- Y 31 is:
- the peptide when the peptide includes the structure X 31 , the peptide may include the following structure:
- the peptide may include the following structure: (Y 31 ) -X 31 -(Z 31 ) b , wherein Y 31 and Z 31 are as
- a is 0 or 1
- b is 0 or 1.
- the peptide may include the following structure:
- Y 32 is;
- the peptide when the peptide includes the structure X 32 , the peptide may include the following
- the peptide may include the following structure:
- the peptide when the peptide includes the structure X 33 , the peptide may include the following structure:
- R 33 are as hereinabove described.
- the peptide when the peptide includes the structure X 33 .
- the peptide may include the following structure:
- the peptide may include the following structure:
- the peptide when the peptide includes the structure X 34 , the peptide may include the following structure:
- Y 34 is:
- the peptide when the peptide includes the structure X 34 , the peptide may include the following structure:
- the peptide may include the following structure:
- the peptide when the peptide includes the structure X 35 , the peptide may include the following structure:
- Y 35 is:
- the peptide when the peptide includes the structure X 35 , the peptide may include the following structure:
- the peptide may include the following structure:
- a is 0 or 1
- b is 0 or 1.
- the peptide when the peptide includes the structure X 36 .
- the peptide may include the following structure:
- Y 36 is:
- R 33 are as hereinabove described.
- the peptide when the peptide includes the structure X 36 , the peptide may include the following structure:
- the peptide may include the following structure: (Y 36 ) a - X 36 (Z 36 ) b , wherein Y 36 , and Z 36 , are as previously defined, a is 0 or 1, and b is 0 or 1.
- the peptide when the peptide includes the structure X 37 , the peptide may includes the structure Y 37 -X 37 , wherein X 37 is as hereinabove described, and Y 37 is:
- the peptide when the peptide includes the structure X 37 .
- the peptide may include the following structure:
- the peptide may include the following structure:
- a is 0 or 1
- b is 0 or 1.
- n 3
- peptide is of one of the following structures as given in the accompanying sequence listing:
- Lys lIe Ala (Lys lIe Ala Gly Lys lIe Ala) 3 (SEQ ID NO: 69) In (SEQ ID NO: 67) and (SEQ ID NO: 68), Xaa is
- amphiphilic peptide includes the following basic structure X 40 :
- the peptide may include the following structure:
- Y 40 is:
- the peptide may include the following structure:
- X 40 -Z 40 wherein X 40 is as hereinabove described and Z 40 is:
- Y 40 ) a -X 40 -(Z 40 ) b wherein Y 40 and Z 40 are as previously defined, a is 0 or 1, and b is 0 or 1.
- the peptide has the following structural formula as given in the accompanying sequence listing:
- the peptide has the following structural formula as given in the accompanying sequence listing:
- the peptide has one of the one of the following structural formulae as given in the accompanying sequence listing:
- the peptide may include the following structural formula:
- n is from 2 to 5.
- n is 3, and the peptide has the following structural formula:
- the peptide may include the following structural formula:
- n is from 2 to 5.
- n 3
- the peptide has the following structural formula:
- the peptide may include the following structural formula:
- n is from 2 to 5.
- n is 3, and the peptide has the following structural formula:
- the peptide may be selected from the group consisting of the following structural formulae as given in the accompanying sequence listing:
- the peptide may be a cecropin or sarcotoxin.
- cecropins includes the basic structure as well as analogues and derivatives thereof. The cecropins and analogues and derivatives thereof are described in Ann. Rev. Microbiol. 1987, Vol. 41, pages 103-26, in particular page 108, and in Christensen, et al., PNAS Vol. 85, pgs. 5072-76, which are hereby incorporated by reference.
- sarcotoxins includes the basic materials as well as analogues and derivatives thereof.
- the sarcotoxins and analogues and derivatives thereof are described in
- amphiphilic peptide includes the following basic structure X 50 ,
- R 41 is a hydrophobic amino acid
- R 42 is a basic hydrophilic or neutral hydrophilic amino acid.
- the peptide includes the basic structure Y 50 -X 50 wherein X 50 is as hereinabove described and Y 50 is:
- R 41 is leucine. In another embodiment, R 41 is leucine. In another
- R 42 is lysine.
- Representative examples of such peptides include those having the following structures:
- the amphiphilic peptide includes the following basic structure X 52 : R 42 -R 41 -R 42 -R 42 -R 41 -R 41 -R 42 -R 42 -R 41 -R 42 -R 42 - wherein R 41 is a hydrophobic amino acid and R 42 is a basic
- hydrophilic or neutral hydrophilic amino acid hydrophilic or neutral hydrophilic amino acid
- R 41 is leucine. In another embodiment, R 41 is leucine. In another
- R 42 is lysine
- the peptide includes the basic structure Y 52 -X 52 , wherein X 52 is as hereinabove described, and Y 52 is:
- the peptide may have the following structure:
- the peptide includes the basic structure X 52 - Z 52 , wherein X 52 is as hereinabove
- the peptide may have the following structure: Lys Leu Lys Lys Leu Leu Lys Lys Leu Lys Lys Leu Leu Lys Lys Leu 5 10
- the peptide may include the structure:
- the peptide includes the following basic structure X 54 :
- R 41 and R 42 are as hereinabove described, and R 43
- the peptide may have the following
- the peptide may have the following amino acids:
- R 42 are as hereinabove described, and R 44 is a neutral
- hydrophilic amino acid or proline hydrophilic amino acid or proline.
- the peptide may include the
- R 41 and R 42 are as hereinabove described.
- the peptide may include the structure:
- the peptide may have one of the following structures:
- the peptide may have the structure (Y 56 ) a -X 56 -(Z 56 ) b , wherein X 56 , Y 56 , and Z 56 are as hereinabove described, a is 0 or 1, and b is 0 or 1.
- the peptide includes the following basic structure X 58 :
- the peptide may include the structure Y 58 -X 58 , wherein X 58 is as hereinabove described, and Y 58 is:
- the peptide includes the structure X 58 -Z 58 , wherein X 58 is as hereinabove described, and Z 58 is:
- the peptide has the following structure:
- the peptide may have the structure
- the peptide includes the following basic structure X 60 :
- the peptide may have the following structure:
- the peptide may include the structure X 60 -Z 60 , wherein6 X 60 is as hereinabove described, and Z 60 is:
- the peptide has a structure selected from the group consisting of:
- the peptide has the structure (a), and a representative example of such a structure is (SEQ ID NO: 107), which is given in the accompanying sequence listing.
- the peptide has the structure (b), and a representative example of such a structure is (SEQ ID NO: 108), which is given in the accompanying sequence listing.
- the peptide has the structure (c), and a representative example of such a structure is (SEQ ID NO: 109) as given the accompanying sequence listing.
- the peptide has the structure (d), and a representative example of such a structure is (SEQ ID NO: 110) as given in the accompanying sequence listing.
- the peptide has the structure (e), and representative examples of such a structure are (SEQ ID NO: 111) and (SEQ ID NO: 112) as given in the accompanying sequence listing.
- the peptide has the following structural formula:
- the peptide is melittin.
- Melittin is an amphipathic peptide consisting of 26 amino acid residues, and is isolated from honeybee (Apis mellifera) venom. The peptide is known to be cytolytic. See Habermann, et al., Hoppe-Seyler's Zeitschrift Physiol. Chem., Vol. 348, pgs. 37-50 (1987). Melittin has the following structural formula as represented by the three-letter amino acid code:
- the peptide purified in accordance with the present invention is an apidaecin.
- apidaecin as used herein includes the basic structure as well as analogues and derivaties thereof. Apidaecins are further described in European Patent Application No. 299,828.
- the peptide may be an amide - or carboxy-terminated peptide represented by the following structural formula, and the numbers below each amino acid residue refer to the position of the residue in the peptide:
- the peptide may be an analogue of such peptide wherein at least one of amino acide residues 1 through 7, 9, 11, 12, 14, 16, or 18 is deleted from the peptide.
- amino acid residues 1, 3, 7, 9, 11, 12, 14, 16, or 18 is deleted from the peptide.
- amino acid residues 1 through 3, 1 through 4, 1 through 5, 1 through 6, and 1 through 7 are deleted from the peptide.
- amino acid residues 1 through 3 or 1 through 4 are deleted from the peptide, and such peptides have the following structural formulae:
- the peptide includes the following structural formula X 62 :
- R 41 is a hydrophobic amino acid
- R 42 is a basic hydrophilic or neutral hydrophilic amino acid.
- R 41 is leucine
- R 42 is lysine.
- the peptide has the following structure:
- the peptide includes the following structural formula X 64 :
- R 41 is a hydrophobic amino acid
- R 42 is a basic hydrophilic or neutral hydrophilic amino acid.
- R 41 is leucine
- R 42 is lysine.
- the peptide has the following structural formula:
- the peptide includes the following structural formula X 66 :
- the peptide may include the following structure:
- R 41 is leucine, and in another embodiment, R 42 is lysine.
- the peptide has the following structural formula: Leu Leu Lys Lys Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys
- the peptide may include the following structural formula X 68 :
- R 42 -R 42 -R 41 wherein R 41 is a hydrophobic amino acid
- R 42 is a basic hydrophilic or neutral hydrophilic amino acid.
- R 41 is leucine, and in another embodiment, R 42 is lysine.
- the peptide has the following structural formula:
- the peptide may also include acetyl or octanoyl groups at the N-terminal, such groups sometimes hereinafter being indicated as Ac- and Oct-, respectively.
- each amino acid residue of the peptide is a D-amino acid residue or a glycine residue.
- each amino acid residue of the peptide is an L-amino acid residue or a glycine residue.
- the amino acid residues of the peptide which are not glycine residues may be a mixture of D-amino acid residues and L-amino acid residues.
- each amino acid residue is a D-amino acid residue or a glycine residue
- dextran molecular weight 70,000-200,000
- deionized water 50 ml of deionized water.
- 0.05 to 0.52g of sodium periodate is added.
- the reaction mixture is stirred for 2 hours at room temperature, and then dialyzed over 4 liters of water for 4 hours using MWCO 1000.
- the oxidized dextran is mixed with 0.3g-1.0g of peptide which is dissolved in sodium bicarbonate buffer (pH 8.0-9.0), and left in a cold room for 6 to 8 hours.
- the mixture was then reduced with from 3 to 30ml of 6% sodium borohydride solution for 6 to 24 hours.
- the reaction is then acidified with acetic acid and dialyzed for 3 to 4 days over 10 liters using MWCO and lyophilized.
- MAP multiple antigenic peptide
- Multiple antigenic peptides are peptides built onto a brached polylysine matrix.
- the polylysine matrix is comprised of 7 lysine residues built on a solid phase resin with a B-alanine spacer.
- Multiple antigenic peptides serve as a model for peptide-protein conjugates.
- the synthesis of the multiple antigenic peptide conjugate is carried out using solid phase methodology on an ABI-431 peptide synthesizer.
- SEQ ID NO: 122 is built on the matrix such that eight copies of (SEQ ID NO: 122) are attached to the matrix.
- the cleavage and purification of the MAP peptides are carried out using standard methodology.
- mice Thirteen groups of CD-1 mice, with each group having 10 mice, were given actinomycin D in order to sensitize the mice to endotoxin. Each mouse ws injected with 20 micrograms of endotoxin.
- a control group of mice received an intraperitoneal challenge of from 0.1mg to 1.0mg of Endotoxin 0111:B4.
- the other groups of mice received an intraperitoneal challenge of from 0.1mg to 1.0mg of Endotoxin 0111:B4 and from 0.1mg to 7mg of one of the peptide conjugates described in Example 1.
- the conjugates had a peptide/polymer ratio of from 3% to 25% wt./wt.
- the conjugates were premixed with the endotoxin for 30 minutes prior to the intraperitoneal challenge. Survivors were assessed on a daily basis for 7 days. The ratio of the number of survivors in each of the conjugate treatment groups at Day 2 and Day 7 to the number of survivors in the control groups is given in Table 1 below.
- ADDRESSEE Carella, Byrne, Bain, Gilfillan,
- NAME/KEY Magainin II peptide.
- NAME/KEY magainin peptide
- NAME/KEY magainin peptide
- NAME/KEY magainin peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6514320A JPH08504210A (en) | 1992-12-07 | 1993-12-06 | Treatment of septic shock using conjugated bioactive peptides |
AU57417/94A AU5741794A (en) | 1992-12-07 | 1993-12-06 | Treatment of septic shock with conjugated biologically active peptides |
EP94903494A EP0672053A1 (en) | 1992-12-07 | 1993-12-06 | Treatment of septic shock with conjugated biologically active peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98744392A | 1992-12-07 | 1992-12-07 | |
US987,443 | 1992-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994013697A1 true WO1994013697A1 (en) | 1994-06-23 |
Family
ID=25533260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/011841 WO1994013697A1 (en) | 1992-12-07 | 1993-12-06 | Treatment of septic shock with conjugated biologically active peptides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0672053A1 (en) |
JP (1) | JPH08504210A (en) |
AU (1) | AU5741794A (en) |
CA (1) | CA2151046A1 (en) |
WO (1) | WO1994013697A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000547A1 (en) * | 1993-06-22 | 1995-01-05 | E.I. Du Pont De Nemours And Company | Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type |
WO1995019370A1 (en) * | 1994-01-18 | 1995-07-20 | Magainin Pharmaceuticals Inc. | Ion-channel forming amphiphilic peptides having n-terminal modifications |
WO1996028468A2 (en) * | 1995-03-09 | 1996-09-19 | Unilever Plc | Amphiphilic peptide and analogs thereof |
US6348445B1 (en) | 1992-06-01 | 2002-02-19 | Magainin Pharmaceuticals, Inc. | Biologically active peptides with reduced toxicity in animals and a method for preparing same |
WO2002080979A3 (en) * | 2001-03-16 | 2003-09-12 | Fresenius Kabi De Gmbh | Conjugate of hydroxyalkyl starch and an active agent |
WO2010040086A1 (en) | 2008-10-02 | 2010-04-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Administration of an adsorbent polymer for treatment of systemic inflammation |
JP2012116850A (en) * | 1995-03-22 | 2012-06-21 | Henry M Jackson Foundation For The Advancement Of Military Medicine | Production of immunogenic construct using soluble carbohydrate activated via organic cyanylating reagent |
US8318899B2 (en) | 2008-01-24 | 2012-11-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Lytic domain fusion constructs and methods of making and using same |
US8840879B2 (en) | 2004-03-11 | 2014-09-23 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US8916518B2 (en) | 2002-03-06 | 2014-12-23 | Fresenius Kabi Deutschland Gmbh | Coupling proteins to a modified polysaccharide |
US9492563B2 (en) | 2012-10-30 | 2016-11-15 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208220A (en) * | 1990-06-27 | 1993-05-04 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase |
US5217956A (en) * | 1988-10-21 | 1993-06-08 | The Children's Hospital Of Philadelphia | Composition and treatment with biologically active peptides and certain anions |
US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
-
1993
- 1993-12-06 CA CA002151046A patent/CA2151046A1/en not_active Abandoned
- 1993-12-06 EP EP94903494A patent/EP0672053A1/en not_active Withdrawn
- 1993-12-06 AU AU57417/94A patent/AU5741794A/en not_active Abandoned
- 1993-12-06 JP JP6514320A patent/JPH08504210A/en active Pending
- 1993-12-06 WO PCT/US1993/011841 patent/WO1994013697A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217956A (en) * | 1988-10-21 | 1993-06-08 | The Children's Hospital Of Philadelphia | Composition and treatment with biologically active peptides and certain anions |
US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
US5208220A (en) * | 1990-06-27 | 1993-05-04 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348445B1 (en) | 1992-06-01 | 2002-02-19 | Magainin Pharmaceuticals, Inc. | Biologically active peptides with reduced toxicity in animals and a method for preparing same |
WO1995000547A1 (en) * | 1993-06-22 | 1995-01-05 | E.I. Du Pont De Nemours And Company | Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type |
US5847047A (en) * | 1993-06-22 | 1998-12-08 | E. I. Du Pont De Nemours And Company | Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type |
WO1995019370A1 (en) * | 1994-01-18 | 1995-07-20 | Magainin Pharmaceuticals Inc. | Ion-channel forming amphiphilic peptides having n-terminal modifications |
WO1996028468A2 (en) * | 1995-03-09 | 1996-09-19 | Unilever Plc | Amphiphilic peptide and analogs thereof |
WO1996028468A3 (en) * | 1995-03-09 | 1997-04-17 | Unilever Plc | Amphiphilic peptide and analogs thereof |
JP2012116850A (en) * | 1995-03-22 | 2012-06-21 | Henry M Jackson Foundation For The Advancement Of Military Medicine | Production of immunogenic construct using soluble carbohydrate activated via organic cyanylating reagent |
WO2002080979A3 (en) * | 2001-03-16 | 2003-09-12 | Fresenius Kabi De Gmbh | Conjugate of hydroxyalkyl starch and an active agent |
EP1671654A3 (en) * | 2001-03-16 | 2008-03-26 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkylstarch and an active agent |
US8916518B2 (en) | 2002-03-06 | 2014-12-23 | Fresenius Kabi Deutschland Gmbh | Coupling proteins to a modified polysaccharide |
US8840879B2 (en) | 2004-03-11 | 2014-09-23 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US8318899B2 (en) | 2008-01-24 | 2012-11-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Lytic domain fusion constructs and methods of making and using same |
US8546535B2 (en) | 2008-01-24 | 2013-10-01 | Esperance Pharmaceuticals, Inc. | Lytic domain fusion constructs and methods of making and using same |
US9255134B2 (en) | 2008-01-24 | 2016-02-09 | Esperance Pharmaceuticals, Inc. | Lytic domain fusion constructs and methods of making and using same |
EP2352568A1 (en) * | 2008-10-02 | 2011-08-10 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Administration of an adsorbent polymer for treatment of systemic inflammation |
EP2352568A4 (en) * | 2008-10-02 | 2013-04-17 | Univ Pittsburgh | Administration of an adsorbent polymer for treatment of systemic inflammation |
US8647666B2 (en) | 2008-10-02 | 2014-02-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Administration of an adsorbent polymer for treatment of systemic inflammation |
WO2010040086A1 (en) | 2008-10-02 | 2010-04-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Administration of an adsorbent polymer for treatment of systemic inflammation |
AU2009298112B2 (en) * | 2008-10-02 | 2015-11-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Administration of an adsorbent polymer for treatment of systemic inflammation |
US9603807B2 (en) | 2008-10-02 | 2017-03-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | Enteral administration of sorbent polymer for treatment and prophylaxis of inflammation |
US9492563B2 (en) | 2012-10-30 | 2016-11-15 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
US10233214B2 (en) | 2012-10-30 | 2019-03-19 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
Also Published As
Publication number | Publication date |
---|---|
JPH08504210A (en) | 1996-05-07 |
EP0672053A1 (en) | 1995-09-20 |
CA2151046A1 (en) | 1994-06-23 |
AU5741794A (en) | 1994-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lai et al. | Strategies employed in the design of antimicrobial peptides with enhanced proteolytic stability | |
AU665945B2 (en) | Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock | |
KR102490489B1 (en) | Novel stapled peptides and uses thereof | |
EP0505497A4 (en) | Wound treatment employing biologically active peptides | |
AU674525B2 (en) | Biologically active peptides having N-terminal substitutions | |
WO1994013697A1 (en) | Treatment of septic shock with conjugated biologically active peptides | |
US20030219854A1 (en) | Methods for producing modified anti-infective peptides | |
JPH08507749A (en) | Treatment of skin malignancies with biologically active peptides | |
US5635479A (en) | Treatment of gynecological malignancies with biologically active peptides | |
US20060148714A1 (en) | Therapeutic peptide-based constructs | |
EP0590044A4 (en) | Composition and treatment with biologically active peptides having c-terminal substitutions | |
CA2125494A1 (en) | Composition and treatment with biologically active peptides and chelating agents | |
US5358933A (en) | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock | |
AU693518B2 (en) | Ion-channel forming amphiphilic peptides having n-terminal modifications | |
WO1997033908A1 (en) | Lytic peptides | |
AU770076B2 (en) | Alpha-conotoxin peptides | |
JPH06504260A (en) | Amphipathic peptide compositions and analogs thereof | |
AU782428B2 (en) | Therapeutic peptide-based constructs | |
HUT67982A (en) | Process for proucing organo-protective peptides and pharmaceutical compositions containing them | |
WO1994005308A1 (en) | Purification of amphiphilic compounds | |
AU1917097A (en) | Lytic peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2151046 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994903494 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994903494 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994903494 Country of ref document: EP |